Skip to content

Trial · Interventional

CompletedPhase 4Results postedRegistry data

The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold

Overview

Status
Completed
Phase
Phase 4
Enrollment
20 participants (actual)
Sponsor
Northwestern University · Other
Design
Randomized · Triple masking
Countries
1 country

United States

Start
Apr 2015
Primary completion
Aug 2015
Completion
Nov 2016
First posted
15 Sept 2015 (estimated)
Last update posted
16 May 2022
Conditions
Healthy

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201520162017
  1. Ph 4

    The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold

    NCT02550093

    Apr 2015 to Nov 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Oxytocin is neurohypophysial peptide that acts mainly as a neuromodulator in the brain.The vast majority of basic science studies suggested a large effect of oxytocin in minimizing acute pain.Few studies have demonstrated an association between plasma levels of oxytocin and pain in humans. Since addictive properties of oxytocin have not been described, the drug may have important application in the management of acute and chronic pain. No studies have examined the effect of intranasal oxytocin on pain sensitivity and threshold.

Interventions

  • Intervention 1Procedure
  • Washout PeriodBehavioral
  • Intervention 2Procedure

Arms2

  • Experimental

    Oxytocin, then Normal Saline

    Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 13 days the same subject will then receive a nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 2 (day 14).

  • Experimental

    Normal Saline, then Oxytocin

    Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing on intervention 1 (day 1). Following a wash-out period of 14 to 15 days the same subject will then receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing on intervention 2 (day 14).

Primary outcomes12

Outcomes the sponsor listed as primary.

  1. Hot and Cold Thermal Sensory Threshold for Pain at Baseline in Degrees Celsius.

    Time frame · Baseline

    Registry description

    Thermal Sensory Threshold for Pain at baseline prior to study drug administration. Evaluation of subjects baseline responses of perception of hot and cold stimuli utilizing the Medoc Pathway Pain \&Sensory Evaluation System (Medoc Ltd, Israel). The baseline response variable was estimated by averaging the subjects response over three trials, with an interval of 30 seconds. A thermode was attached to the subjects hand and the subject was asked to press a mouse button when they perceive the sensation of heat pain or cold pain. The temperature range was 51C to 0C.

  2. Hot and Cold Thermal Sensory Threshold for Pain at 45 Minutes in Degrees Celsius.

    Time frame · 45 minutes

    Registry description

    Thermal Sensory Threshold for Pain at 45 minutes after study drug administration. Evaluation of subjects responses of perception of hot and cold stimuli utilizing the Medoc Pathway Pain \&Sensory Evaluation System (Medoc Ltd, Israel). The response variable was estimated by averaging the subjects response over three trials, with an interval of 30 seconds. A thermode was attached to the subjects hand and the subject was asked to press a mouse button when they perceive the sensation of heat pain or cold pain. The temperature range was 51C to 0C.

  3. Hot and Cold Thermal Sensory Threshold for Pain at 90 Minutes in Degrees Celsius.

    Time frame · 90 minutes

    Registry description

    Thermal Sensory Threshold for Pain at 90 minutes after study drug administration. Evaluation of subjects responses of perception of hot and cold stimuli utilizing the Medoc Pathway Pain \&Sensory Evaluation System (Medoc Ltd, Israel). The response variable was estimated by averaging the subjects response over three trials, with an interval of 30 seconds. A thermode was attached to the subjects hand and the subject was asked to press a mouse button when they perceive the sensation of heat pain or cold pain. The temperature range was 51C to 0C.

  4. Mechanical Pain Threshold for Pain at Baseline in Grams.

    Time frame · Baseline

    Registry description

    Mechanical pain threshold for pain at baseline utilizing a digital electrovonfrey anesthesiometer (IITC model Alemo 2290-4; Woodland Hills, CA, USA). The subjects response to painful stimulus was recorded in grams. Each variable was estimated by averaging a participant's responses over 3 trials, with an intertrial interval of 30 s. The lower amount in grams the more sensitive you are to pain.

  5. Mechanical Pain Threshold for Pain at 45 Minutes in Grams.

    Time frame · 45 minutes

    Registry description

    Mechanical pain threshold for pain at 45 minutes utilizing a digital electrovonfrey anesthesiometer (IITC model Alemo 2290-4; Woodland Hills, CA, USA). The subjects response to painful stimulus was recorded in grams. Each variable was estimated by averaging a participant's responses over 3 trials, with an intertrial interval of 30 s. The lower amount in grams the more sensitive you are to pain.

  6. Mechanical Pain Threshold for Pain at 90 Minutes in Grams.

    Time frame · 90 minutes

    Registry description

    Mechanical pain threshold for pain at 90 minutes utilizing a digital electrovonfrey anesthesiometer (IITC model Alemo 2290-4; Woodland Hills, CA, USA). The subjects response to painful stimulus was recorded in grams. Each variable was estimated by averaging a participant's responses over 3 trials, with an intertrial interval of 30 s. The lower amount in grams the more sensitive you are to pain.

  7. Suprathreshold Magnitude for Pain at Baseline Measured in Visual Analog Pain Scores.

    Time frame · Baseline

    Registry description

    Supra-threshold magnitude for pain was assessed utilizing the Medoc Pathway System with contact heat evoked potential simulator at 49 degrees Celsius. Visual analog pain score ranges from 0 (no pain) to 10 (worst pain imaginable).

  8. Suprathreshold Magnitude for Pain at 45 Minutes Measured in Visual Analog Pain Scores.

    Time frame · 45 minutes

    Registry description

    Supra-threshold magnitude for pain was assessed utilizing the Medoc Pathway System with contact heat evoked potential simulator at 49 degrees Celsius. Visual analog pain score ranges from 0 (no pain) to 10 (worst pain imaginable).

  9. Suprathreshold Magnitude for Pain at 90 Minutes Measured in Visual Analog Pain Scores.

    Time frame · 90 minutes

    Registry description

    Supra-threshold magnitude for pain was assessed utilizing the Medoc Pathway System with contact heat evoked potential simulator at 49 degrees Celsius. Visual analog pain score ranges from 0 (no pain) to 10 (worst pain imaginable).

  10. Thermal Wind-up Pain Assessment at Baseline

    Time frame · Baseline

    Registry description

    Using a Visual Analog Scale (VAS) subjects will be asked to rate the painfulness of the stimulus for thermal wind-up pain utilizing the medoc pathway system. Each VAS score was recorded over 10 trials, with an interval of 3s. The average VAS score was reported. Visual analog scale ranges from 0 (no pain) to 10 (worst pain imaginable).

  11. Thermal Wind-up Pain at 45 Minutes

    Time frame · 45 minutes

    Registry description

    Using a Visual Analog Scale (VAS) subjects will be asked to rate the painfulness of the stimulus for thermal wind-up pain utilizing the medoc pathway system. Each VAS score was recorded over 10 trials, with an interval of 3s. The average VAS score was reported. Visual analog scale ranges from 0 (no pain) to 10 (worst pain imaginable).

  12. Thermal Wind-up Pain at 90 Minutes

    Time frame · 90 minutes

    Registry description

    Using a Visual Analog Scale (VAS) subjects will be asked to rate the painfulness of the stimulus for thermal wind-up pain utilizing the medoc pathway system. Each VAS score was recorded over 10 trials, with an interval of 3s. The average VAS score was reported. Visual analog scale ranges from 0 (no pain) to 10 (worst pain imaginable).

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· Baseline

Hot and Cold Thermal Sensory Threshold for Pain at Baseline in Degrees Celsius.

GroupValue (degrees Celsius)Spread
Oxytocin43.934.18
Normal Saline43.04.34
Primary outcomeMean· 45 minutes

Hot and Cold Thermal Sensory Threshold for Pain at 45 Minutes in Degrees Celsius.

GroupValue (degrees Celsius)Spread
Oxytocin43.603.68
Normal Saline43.423.98
Primary outcomeMean· 90 minutes

Hot and Cold Thermal Sensory Threshold for Pain at 90 Minutes in Degrees Celsius.

GroupValue (degrees Celsius)Spread
Oxytocin43.943.97
Normal Saline43.953.80
Primary outcomeMean· Baseline

Mechanical Pain Threshold for Pain at Baseline in Grams.

GroupValue (Grams)Spread
Oxytocin194.90117.52
Normal Saline223.31149.56
Primary outcomeMean· 45 minutes

Mechanical Pain Threshold for Pain at 45 Minutes in Grams.

GroupValue (Grams)Spread
Oxytocin195.07145.41
Normal Saline197.49124.71
Primary outcomeMean· 90 minutes

Mechanical Pain Threshold for Pain at 90 Minutes in Grams.

GroupValue (Grams)Spread
Oxytocin198.76141.41
Normal Saline208.77124.97
Primary outcomeMean· Baseline

Suprathreshold Magnitude for Pain at Baseline Measured in Visual Analog Pain Scores.

GroupValue (scores on a scale)Spread
Oxytocin2.901.65
Normal Saline3.021.88
Primary outcomeMean· 45 minutes

Suprathreshold Magnitude for Pain at 45 Minutes Measured in Visual Analog Pain Scores.

GroupValue (scores on a scale)Spread
Oxytocin2.581.37
Normal Saline2.671.59

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
OxytocinSubjects received nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing.0 / 200 / 200 / 20
Normal SalineSubjects received nasal spray(s) into each nostril of Normal Saline prior to Thermal Evaluation System Testing.0 / 200 / 200 / 20

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies6

Studies that cite this trial.

Studies with results

3 studies on this page

Indexing hint: Systematic review · 2014

3 results

Oxytocin and pain: a systematic review and synthesis of findings.

Rash et al. 2014The Clinical journal of paincited by 131

PMID 23887343DOI 10.1097/ajp.0b013e31829f57dfPUB-23887343

Full text at the publisher3 results

Indexing hint: Systematic review · 2011

3 results

A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

MacDonald et al. 2011Psychoneuroendocrinologycited by 276

PMID 21429671DOI 10.1016/j.psyneuen.2011.02.015PUB-21429671

Full text at the publisher3 results

Indexing hint: Randomized controlled trial · 2008

3 results

Effects of oxytocin and prosocial behavior on brain responses to direct and vicariously experienced pain.

Singer et al. 2008Emotion (Washington, D.C.)cited by 172

PMID 19102589PMC2672051DOI 10.1037/a0014195PUB-19102589

Rights unknown3 results

More studies

3 studies on this page

PubMed tag: none · 2013

The interaction between the oxytocin and pain modulation in headache patients.

Wang et al. 2013Neuropeptidescited by 86

PMID 23375440DOI 10.1016/j.npep.2012.12.003PUB-23375440

Full text at the publisher
Publisher page

Indexing hint: Review · 2012

Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction.

Yamasue et al. 2012The Journal of neuroscience : the official journal of the Society for Neurosciencecited by 106

PMID 23055480PMC6622380DOI 10.1523/jneurosci.3327-12.2012PUB-23055480

Free to read · publisher termsCC BY-NC
Read at source

Indexing hint: Randomized controlled trial · 2006

Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants.

Fewtrell et al. 2006Archives of disease in childhood. Fetal and neonatal editioncited by 52

PMID 16223754PMC2672698DOI 10.1136/adc.2005.081265PUB-16223754

Rights unknown
Source link

Eligibility

Who could join, as posted.

Sex
All
Age
from 20 Years up to 35 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Healthy males and females volunteers, English speaking Exclusion Criteria: * Pregnancy, lactation, allergy to preservatives, mental disease, any chronic pain and any current use of analgesics, anxiety or depression.

PepBank is a research reference. Talk to a doctor before you use any peptide.